Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tildacerfont treatment in males with congenital adrenal hyperplasia reduced androgen levels and improved markers of testicular function, suggesting potential benefits for male reproductive health.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

Ritlecitinib works well and is safe for treating alopecia areata.

This study found therapeutic isolated limb perfusion with melphalan to be effective for in-transit melanoma metastases on a limb, with a high response rate and transient systemic toxicity.

This study found that while some patients with severe alopecia areata responded to high-dose prednisolone, the response was inconsistent and the therapy's risks prevent recommending it for general use.

This case series found that patients with the NUDT15 415C>T variant experienced severe azathioprine toxicity, suggesting genotype-based dosing could reduce adverse effects.

This case report describes severe agranulocytosis and alopecia in a Japanese woman after starting azathioprine, highlighting the potential role of NUDT15 genetic screening in preventing adverse reactions to the drug.

This case report describes a 22-year-old woman who developed persistent, non-scarring hair loss and premature ovarian failure following a myeloablative umbilical cord transplant for acute myeloid leukemia.

This case report describes a patient with chronic renal failure on hemodialysis who experienced hair depigmentation while taking heptaminol, with the condition reversing after discontinuing the medication; the exact mechanism causing the color change is still unclear.

This article discusses systemic lupus erythematosus, covering its clinical features, treatments, and the recent FDA approval of belimumab, but does not present new clinical results.

This study reviewed a corticosteroid treatment regimen for a 52-year-old woman with extensive alopecia areata, showing significant hair regrowth and sustained remission over 12 months, suggesting oral mini-pulse therapy as a viable alternative for those ineligible for JAK inhibitors.

This review summarizes the use of chlormadinone acetate for hormone replacement therapy and contraception, highlighting its anti-androgenic effects, contraceptive efficacy, and clinical tolerability, without offering new clinical results.

This study found that in circulating tumor cells from non-invasive liquid biopsies, the GG genotype of the CYP3A5 A6986G affects longer disease-free survival in DLBCL patients, highlighting the significance of circulating biomarkers for prognostic evaluation.

This study tested a folate-conjugate drug delivery system and found its cytotoxicity depends on whether the treated cells overexpress folate receptors, suggesting potential for targeted chemotherapy.

Low-dose naltrexone helps improve symptoms and stabilize frontal fibrosing alopecia and lichen planopilaris.

This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.

This study found that a series of three monthly courses of medium-dose prednisolone pulse therapy was effective and well tolerated in most patients with active, multifocal alopecia areata but not in those with totalis/universalis.

This study reported that peginterferon alpha-2a showed high early and sustained virologic response rates in Albanian hemodialyzed patients with hepatitis C, despite causing several adverse effects.

Men with Addison disease should be screened for X-linked adrenoleukodystrophy if they have hair loss.

This case report describes two patients experiencing a bortezomib-induced skin eruption as multiple plaques on the trunk, with the lesions resolving spontaneously in about a week.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This review discusses the potential role of JAK inhibitors, like ruxolitinib, as emerging therapeutic agents in dermatology, but reports no new clinical results.

This case report details a 45-year-old woman with SLE who experienced severe leukopenia and hair loss attributed to azathioprine, suggesting the importance of recognizing these potential adverse effects for timely intervention.

This study presented a case where budesonide was insufficient to maintain remission in autoimmune hepatitis, suggesting it may be less effective than prednisolone and associated with notable steroid side effects.

This case report describes a 32-year-old woman with a history of undifferentiated connective tissue disease who presented with cardiogenic shock, and endomyocardial biopsy revealed giant cell myocarditis, possibly indicating an association with her autoimmune condition.

This case report found that adding lokivetmab to prednisolone treatment improved and maintained remission of pruritus in a dog with cutaneous epitheliotropic lymphoma.

This study investigated paternal drug exposure using FDA data and identified significant associations with reproductive health risks, including congenital anomalies linked to immunosuppressive drugs, and emphasized specific risk combinations like biologics and abortion, diazepam and small for date baby, and finasteride and cryptorchidism.

Low-dose oral naltrexone may help reduce inflammation in some scarring alopecia patients.